Landmark study links DAAs to better survival in hep C patients

The results counter an inflammatory Cochrane review that questioned the drugs, say gastroenterologists
Professor Greg Dore
Professor Greg Dore.

The first prospective longitudinal study of outcomes from treatment with direct-acting antivirals (DAAs) suggests the drugs could halve mortality rates among patients with hepatitis C.

The five-year French study of almost 10,000 patients, published in the Lancet, shows that patients who received DAAs had a 52% lower risk of death compared with untreated patients at any time during the follow-up of nearly three years.